cpd-22

cpd-22 is a potent and selective small molecule inhibitor of integrin-linked kinase (ILK). ILK is a serine/threonine protein kinase and scaffold protein that plays a critical role in mediating signals between the extracellular matrix and the intracellular compartment, influencing processes such as cell survival, proliferation, and epithelial-mesenchymal transition (EMT). By inhibiting ILK, cpd-22 disrupts downstream oncogenic signaling pathways, notably the phosphorylation of Akt at Ser473 and the activation of the Wnt/β-catenin pathway. In preclinical research, particularly in ovarian cancer models, cpd-22 has demonstrated the ability to suppress the proliferation and tumor-initiating capacity of cancer stem cells, downregulate the expression of the Wnt receptor Frizzled 7 (Fzd7), and sensitize platinum-resistant cells to chemotherapy, leading to increased apoptosis.